[go: up one dir, main page]

CO2017005624A2 - Composiciones oftálmicas estabilizadas de omega 3 - Google Patents

Composiciones oftálmicas estabilizadas de omega 3

Info

Publication number
CO2017005624A2
CO2017005624A2 CONC2017/0005624A CO2017005624A CO2017005624A2 CO 2017005624 A2 CO2017005624 A2 CO 2017005624A2 CO 2017005624 A CO2017005624 A CO 2017005624A CO 2017005624 A2 CO2017005624 A2 CO 2017005624A2
Authority
CO
Colombia
Prior art keywords
ophthalmic compositions
stabilized
stabilized omega
omega
keratoconjunctivitis
Prior art date
Application number
CONC2017/0005624A
Other languages
English (en)
Inventor
Anuradha V Gore
Jaya Giyanani
Sukhon Likitlersuang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54784036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005624(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO2017005624A2 publication Critical patent/CO2017005624A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/55Linaceae (Flax family), e.g. Linum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones oftálmicas estabilizadas que contienen aceites omega 3, que son útiles como lágrimas artificiales y como composiciones oftálmicas para diagnosticar, tratar o prevenir la queratoconjuntivitis o síndrome del ojo seco en un ser humano u otro mamífero.
CONC2017/0005624A 2014-11-25 2017-06-06 Composiciones oftálmicas estabilizadas de omega 3 CO2017005624A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083980P 2014-11-25 2014-11-25
PCT/US2015/062213 WO2016085885A1 (en) 2014-11-25 2015-11-23 Stabilized omega-3 ophthalmic compositions

Publications (1)

Publication Number Publication Date
CO2017005624A2 true CO2017005624A2 (es) 2017-10-20

Family

ID=54784036

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005624A CO2017005624A2 (es) 2014-11-25 2017-06-06 Composiciones oftálmicas estabilizadas de omega 3

Country Status (17)

Country Link
US (5) US10279005B2 (es)
EP (1) EP3223794A1 (es)
JP (1) JP6768653B2 (es)
KR (1) KR102487299B1 (es)
CN (1) CN107106483B (es)
AU (1) AU2015353701B2 (es)
CA (1) CA2967413C (es)
CL (1) CL2017001301A1 (es)
CO (1) CO2017005624A2 (es)
IL (1) IL252161B (es)
MX (2) MX372988B (es)
NZ (1) NZ732058A (es)
PH (1) PH12017500922A1 (es)
RU (1) RU2697844C9 (es)
SG (1) SG11201704167PA (es)
UA (1) UA121399C2 (es)
WO (1) WO2016085885A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3032695C (en) * 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
JP7311160B2 (ja) 2017-08-18 2023-07-19 アクリビスタ エルエルシー ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物
CN111587111B (zh) 2017-08-27 2023-12-19 罗得技术公司 用于治疗眼科病症的药物组合物
CN109364153A (zh) * 2018-11-30 2019-02-22 河南科高中标检测技术有限公司 一种缓解和治疗电子辐射类视疲劳的组合物、制备方法及其应用
US11723838B2 (en) 2019-05-02 2023-08-15 TearClear Corp. Preservative removal from eye drops
CN115397374A (zh) * 2019-12-19 2022-11-25 特清公司 从滴眼剂中去除防腐剂
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
KR102365009B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
US11478378B2 (en) 2020-08-05 2022-10-25 TearClear Corp. Systems and methods for preservative removal from ophthalmic formulations
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
IT202300000006A1 (it) 2023-01-02 2024-07-02 Offhealth Spa “formulazione liposomiale di curcumina per uso oftalmico e suo metodo di preparazione industriale atto a stabilizzare nel tempo la concentrazione della stessa curcumina”
WO2025072929A1 (en) * 2023-09-28 2025-04-03 The Regents Of The University Of California Methods and compositions of treating age-related conditions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
DE3066859D1 (en) 1979-10-26 1984-04-12 Smith & Nephew Ass Autoclavable emulsions
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
ATE109970T1 (de) 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
BE1003578A4 (fr) 1988-10-26 1992-04-28 Sandoz Sa Nouvelles compositions ophtalmiques a base d'une cyclosporine.
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
KR930005321B1 (ko) 1989-08-03 1993-06-17 에자이가부시끼가이샤 점안액의 광 안정화법 및 그로 부터 수득한 점안액
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CN1160346A (zh) 1994-09-14 1997-09-24 大正制药株式会社 用于修复角膜损伤的滴眼液
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
ATE273026T1 (de) 1998-11-13 2004-08-15 Continental Projects Ltd Komplexe von hyaluronic saure/carnitinen und pharmazeutische und kosmetische zusammensetzungen
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
PT2153819E (pt) 2000-07-14 2012-11-14 Allergan Inc Utilização de um componente para aumento de solubilidade numa composição aquosa compreendendo tartarato de brimonidina
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
CN1245166C (zh) 2000-11-08 2006-03-15 生物概念实验室 改进的含有单糖类作为防腐增强剂的眼科和隐形眼镜用溶液
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
EP1611883A1 (en) 2003-03-26 2006-01-04 Menicon Co., Ltd. Composition for ophthalmic use
CN1856251A (zh) * 2003-06-11 2006-11-01 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CN101668511A (zh) 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
CA2741288A1 (en) 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
ES2646338T3 (es) 2009-06-05 2017-12-13 Allergan, Inc. Lágrimas artificiales y usos terapéuticos
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
EP2790673B1 (en) * 2011-12-16 2017-07-05 Allergan, Inc. Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers (soluplus)
CN102934703B (zh) * 2012-11-13 2015-07-15 中国食品发酵工业研究院 一种亚麻籽油微胶囊及其生产方法

Also Published As

Publication number Publication date
KR102487299B1 (ko) 2023-01-10
KR20170086111A (ko) 2017-07-25
AU2015353701B2 (en) 2021-03-25
US20240299480A1 (en) 2024-09-12
IL252161B (en) 2020-09-30
IL252161A0 (en) 2017-07-31
US20190298790A1 (en) 2019-10-03
MX2017006474A (es) 2017-09-12
US10279005B2 (en) 2019-05-07
BR112017010987A2 (pt) 2018-02-14
NZ732058A (en) 2023-06-30
MX372988B (es) 2020-04-06
RU2697844C9 (ru) 2019-10-01
AU2015353701A1 (en) 2017-06-01
CA2967413A1 (en) 2016-06-02
EP3223794A1 (en) 2017-10-04
US20160143977A1 (en) 2016-05-26
RU2697844C2 (ru) 2019-08-21
CA2967413C (en) 2023-08-15
CL2017001301A1 (es) 2018-01-26
MX2020004076A (es) 2020-07-29
US20220143122A1 (en) 2022-05-12
PH12017500922A1 (en) 2017-11-20
WO2016085885A1 (en) 2016-06-02
RU2017117558A3 (es) 2019-06-05
CN107106483B (zh) 2021-04-16
RU2017117558A (ru) 2018-12-26
JP6768653B2 (ja) 2020-10-14
UA121399C2 (uk) 2020-05-25
US20250228913A1 (en) 2025-07-17
SG11201704167PA (en) 2017-06-29
JP2017535578A (ja) 2017-11-30
CN107106483A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
CO2017005624A2 (es) Composiciones oftálmicas estabilizadas de omega 3
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
MX389460B (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
MX2017014375A (es) Moduladores del ccr2.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
WO2016040775A8 (en) Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
MX387804B (es) Metodos para tratar presion intraocular con activadores de tie-2
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
MX2016007278A (es) Metodos y composiciones farmaceuticas para la expresion de un polinucleotido de interes en el epitelio pigmentario retiniano de un sujeto.
MY193650A (en) Extracellular matrix compositions
AR100231A1 (es) Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea
MX2019009606A (es) Bis-compuestos para dispositivos opticamente activos.
SI3288588T1 (sl) Izboljšana sredstva za prečno povezovanje kolagenskih vlaken za uporabo pri zdravljenju kornealne ektazije
MX392383B (es) Metodos para tratar afecciones oculares.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
MX377022B (es) Composiciones de lágrimas artificiales.
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας